Authors:

R. Niiruri, I. Narayani, K. Ariawati, S. Herawati

Abstract:

“Abstract Objective: P-glycoprotein (P-gp) overexpression on neoplastic cells can deteriorate the therapeutic outcome on cancer patients. P-gp plays important role on drug efficacy and toxicity. This research aimed to measure P-gp expression on children with Acute Lymphoblastic Leukemia (ALL) on Sanglah Hospital, Denpasar. Method: Flowcytometry method was used to measure P-gp expression level on Bone Marrow samples from pediatric patients (0-12 years old) who were newly diagnosed with ALL in Sanglah Hospital. P-gp overexpression were based on the percentage of cell stained. Ten percent of P-gp expression were considered as the cut-off value of P-gp overexpression. Result: On this study, 11 samples were obtained with the range value of 56-97% on P-gp expression. Conclusion: All 11 patients had P-gp overexpression.”

Keywords

Keyword Not Available

Downloads:

Download data is not yet available.

References

  • REFERENCES
  • [1] L. M. Hodges, S. M. Markova, L. W. Chinn, J. M. Gow, D. L.
  • Kroetz, T. E. Klein, and R. B. Altman. (2011, March). Very
  • important pharmacogene summary: ABCB1 (MDR1, Pglycoprotein).
  • Pharmacogenet Genomics. [Online]. 21(3). pp. 152–161. Available:
  • https://www.ncbi.nlm.nih.gov/pubmed/20216335
  • [2] L. Yan-Hong, W. Yong-Hua, L. Yan, Y. Ling. (2006, February).
  • MDR1 Gene Polymorphisms and Clinical Relevance. Acta Genetica
  • Sinica. [Online]. 33 (2). pp. 93–104. Available:
  • http://www.sciencedirect.com
  • /science/article/pii/S0379417206600279?via%3Dihub
  • [3] K. L. Fung and M.M. Gotte. (2009, May). A synonymous
  • polymorphism in a common MDR1 (ABCB1) haplotype shapes
  • protein function. Biochim Biophys Acta. [Online]. 1794(5). pp. 860–
    1. Available: https://www.ncbi.nlm.nih.gov/pubmed/19285158
  • [4] H.J. Broxterman. 1996. How to Probe Clinical Tumour Samples for
  • P-glycoprotein and Multidrug Resistance-associated Protein.
  • European Journal of Cancer. [Online]. 33A(6). pp. 1024-1033.
  • Available: https://www.ncbi.nlm.nih.gov /pubmed/8763344
  • [5] A. L. Dogan, A. Kars, H. Canpinar, D. Güç, M. Hayran, W. E. Criss,
  • E. Kansu. (2004). Prediction of Clinical Response to Chemotherapy
  • by In Vitro Chemosensitivity Assay In Acute Leukemia. Turkish
  • Journal of Cancer. [Online]. 34(2). pp. 75-80. Available:
  • http://www.turkjcancer.org/pdf/pdf_ TJC_367.pdf
  • [6] V. NÜssler, R. Pelka-Flescher, H. Zwierzina, C. Nerl, B. Beckert, F.
  • Gieseler, H. Diem, Ledderose G, E. Gullis, H. Sauer, W. Wilmanns.

  • Journal of Health Sciences and Medicine UNUD Journals, Vol. 1 No. 1, February 2017

  • 41
  • (1996, July). P-glycoprotein expression in patients with acute
  • leukemia-clinical relevance. Leukemia. [Online]. 10(Suppl 3). pp.
  • S23-S31. Available: https://www.ncbi.nlm.nih.gov/pubmed/8656697
  • [7] V. NÜssler, R. Pelka-Flescher, H. Zwierzina, C. Nerl, B. Beckert, E.
  • Gullis, F. Gieseler, S. Bock, R. Bartl, P. E. Petrides, et al. (1994).
  • Clinical Importance of P-glycoprotein-related resistance in Leukemia
  • and Myelodysplastic Syndromes-First Experience with Their
  • Reversal. Ann. Hematol. [Online]. 69 (Suppl 1). pp. S25-9.
  • Available: http://link.springer.com/article/10.1007/BF01757351
  • [8] I B. Mudita. (2007). Pola Penyakit dan Karakteristik Pasien Hemato
  • Onkologi Bagian Ilmu Kesehatan Anak Fakultas Kedokteran
  • Universitas Udayana / Rumah Sakit Sanglah Periode 2000-2005. Sari
  • Pediatri. [Online]. 9(1). pp. 13-16. Available:
  • https://www.researchgate.net/publication/312404291_Pola_Penyakit
  • _dan_Karakteristik_Pasien_Hemato_Onkologi_Bagian_Ilmu_Keseha
  • tan_Anak_Fakultas_Kedokteran_Universitas_UdayanaRS_Sanglah_
  • Denpasar_Periode_2000-2005
  • [9] S. V. Ambudkar, C. Kimchi-Sarfaty, Z. E. Sauna and M. M.
  • Gottesman. (2003). P-glycoprotein: from genomics to mechanism.
  • Oncogene. [Online]. 22. pp. 7468–7485. Available:
  • https://www.ncbi.nlm.nih.gov/pubmed/14576852
  • [10] J. M. Gow, L. M. Hodges, L. W. Chin, D. L. Kroetz. (2008).
  • Substrate – Dependent Effect of Human ABCB1 Coding
  • Polymorphisms. J Phamacol Exp Ther. [Online]. 325(2). pp. 435 -
    1. Available: http://jpet.aspetjournals.org/content/jpet/325/2/435.
  • full.pdf
  • [11] C. Kimchi-Sarfathy, J. M. Oh, I. W. Kim, Z. E. Sauna, A. M.
  • Calcagno. S. V. Ambudkar, M. M. Gottesman. (2007). A Silent
  • Polymorphism in the MDR-1 Gene Changes Substrate Specificity.
  • Science. [Online]. 315. pp. 525-528. Available:
  • https://www.ncbi.nlm.nih.gov/pubmed/17185560
  • [12] N. N. Salama, Z. Yang, T. Bui, R. J. Ho. (2006). MDR 1 Haplotypes
  • Significantly Minimize Intracellular Uptake and Transcellular P-Gp
  • Substrate Transport in Recombinant LLC-PK1 Cells. Journal of
  • Pharmaceutical Sciences. [Online]. 95. pp. 2293 – 2308. Available:
  • https://www.ncbi.nlm.nih.gov/pubmed/16883550
  • [13] D. L. Kroetz, C. Pauli-Magnus, L. M. Hodges, C. C. Huang, M.
  • Kawamoto, S. J. John, D. Stryke, T. E. Ferrin, J. De Young, T.
  • Taylor, E. J. Carlson, I. Herskowitz, K. M. Giacomini, A. G. Clark.
  • (2003). Sequence Diversity And Haplotype Structure in Human
  • ABCB1 (MDR1, Multi Drug Resistance Transporter) Gene.
  • Pharmacogenetics. [Online]. 13. pp. 481-494. Available:
  • https://www.ncbi.nlm.nih.gov/pubmed/16883550
  • [14] M. K. Leabman, C. C. Huang, J. D. Young, E J. Carlson, T. R.
  • Taylor, D. L. M. Cruz, S. J John, D. Stryke, M. Kawamoto, T. J.
  • Urban, D. L. Kroetz, T. E. Ferrin, A. G. Clark, N. Risch, I.
  • Herskowitz, K. M. Giacomini. (2003). Natural Variation In Human
  • Membrane Transpoter Genes Reveals Evolutionary and Functional
  • Constrains. Proc Natl Acad Sci USA. [Online]. 100. pp. 5896 – 5901.
  • Available: http://www.pnas.org/content/100/10/5896.full.pdf
  • [15] S. Hoffmeyer, O. Burk, O Richter, H. P. Arnold, J. Brockmoller, A.
  • Johne, I. Cascorbi, T. Gerloff, I. Roots, M. Eichelbaum, U.
  • Brinkmann. (2000). Functional polymorphisms of the human
  • multidrug resistance gene: multiple sequence variations and
  • correlation of one allele with P-glycoprotein expression and activity
  • in vivo. Proc NatlAcad Sci USA. [Online]. 97. pp. 3473-3478.
  • Available: https://www.ncbi.nlm.nih.gov/pubmed/10716719
  • [16] R. B. Kim, B. F. Leake, E. F. Choo, G. K. Dresser, S. V. Kubba, U. I.
  • Schwarz, A. Taylor, H. G. Xie, J. McKinsey, S. Zhou, L. B. Lan, J.
  • D. Schuetz, E. G. Schuetz, G. R. Wilkinson. (2001). Identification of
  • functionally variant MDR1 alleles among European Americans and
  • African Americans. Clin Pharmacol Ther. [Online]. 70. pp. 189-199.
  • Available: https://www.ncbi.nlm.nih.gov/pubmed/11503014
  • [17] M. M. Ameyaw, F. Regateiro, T. Li, X. Liu, M. Tariq, A. Mobarek,
  • N. Thornton, G. O. Folayan, J. Githang’a, A. Indalo, D. Ofori-Adjei,
  • D. A. Price-Evans, H. L. McLeod. (2001). MDR1 pharmacogenetics:
  • frequency of the C3435T mutation in exon 26 is significantly
  • influenced by ethnicity. Pharmacogenetics. [Online]. 11. pp. 217-
    1. Available: https://www.ncbi.nlm.nih.gov/pubmed/11337937
  • [18] M. Saidijam, H. Mahjub, N. Shabab, R. Yadegarazari, (2015).
  • Simultaneous Analyisis of Multidrug Resistance 1 (MDR-1)
  • C3435T, G 2677 T/A, and C1236T Genotype in Hamadan City
  • Population, West of Iran. Iranian Biomedical Journal. [Online].
  • 19(1). pp. 57-62. Available:
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322234/
  • [19] A. J. Brambilla-Tapia. (2013). MDR 1 (ABCB1) polymorphisms:
  • functional effects and Clininal Implications. Revista de Investigacon
  • Clinica. [Online]. 65(5). pp. 445 –454. Available:
  • https://www.ncbi.nlm.nih. gov/pubmed/24687344
  • [20] K. Tang, S. M. Ngoi, P. C. Gwee, J. M. Chua, E. J. Lee, S. S. Chong
  • and C. G. Lee. (2002). Distinct Haplotype Profiles And Strong
  • Linkage Disequilibrium At The MDR1 Multidrug Transporter Gene
  • Locus In Three Ethnic Asian Populations. Pharmacogenetics.
  • [Online]. 12. pp. 437–450. Available:https://www.ncbi.nlm.nih.gov/
  • pubmed/12172212
  • [21] C. J. Chen, D. Clark, K. Ueda, I. Pastan, M. M. Gottesman and I. B.
  • Roninson. (1990, January). Genomic Organization of Human
  • Multidrug Resistance (MDR1) Gene and Origin of P-Glycoprotein. J
  • Biol Chem. [Online]. 265(1). pp. 506-514. Available:
  • https://www.ncbi.nlm.nih.gov/pubmed/1967175
  • [22] D. Vivona, L. T. Lima, A. C. Rodrigues, C. T. Bueno, G. K. S.
  • Alcantara, L. S. R. Barbos, V. T. D. M. Hungria, C. S. Chiattone, M.
  • D. L. L. D. Chauffaille, E. M. Guerra-Shinohara. (2014). ABCB1
  • Haplotype are Associated with P-gp Activity and Affect a Major
  • Molecular Response in Chronic Myeloid Leukemia Patients Treated
  • with A standard Dose of Imatinib. Oncology Letters. [Online]. 7. pp.
  • 1313-1319. Available: https://www.ncbi.nlm.nih.gov/pubmed/24660
  • 038
  • [23] K. L. Fung and M. M. Gottesman. (1794). A synonymous
  • polymorphism in a common MDR1 (ABCB1) haplotype shapes
  • protein function. Biochim Biophys Acta. 1794. pp. 860-871.
  • [24] A. Ashariati, (2008, October). Polymorphism C3435T of The MDR-
  • 1 Gene Predict Response to Preoperative Chemotherapy in Locally
  • Advanced Breast Cancer with Her 2/ neu Expression. Acta med
  • Indones, [Online]. 40(4). pp. 187-91. Available:
  • https://www.ncbi.nlm.nih.gov/pubmed/19151448
  • [25] A. F. List, K. J. Kopecky, C. L. Willman, D. R. Head, D. L. Persons,
  • M. L. Slovak, R. Dorr, C. Karanes, H. E. Hynes, J. H. Doroshow, M.
  • Shurafa and F. R. Appelbaum. (2001). Benefit of cyclosporine
  • modulation of drug resistance in patients with poor-risk acute
  • myeloid leukemia: a Southwest Oncology Group study. Blood,
  • [Online]. 98. pp. 3212–3220. Available:
  • https://www.ncbi.nlm.nih.gov/pubmed ?cmd=Link &dbFrom
  • =PubMed&from_uid=8874180

PDF:

https://jurnal.harianregional.com/jhsm/full-34823

Published

2017-02-01

How To Cite

NIIRURI, R. et al. P-Glycoprotein Expression on Patients with Acute Lymphoblastic Leukemia.Journal of Health Sciences and Medicine, [S.l.], v. 1, n. 1, p. 39-41, feb. 2017. ISSN 2622-0555. Available at: https://ojs.unud.ac.id/index.php/JHSM/article/view/34823. Date accessed: 28 Aug. 2025. doi:https://doi.org/10.24843/JHSM.2017.v01.i01.p10.

Citation Format

ABNT, APA, BibTeX, CBE, EndNote - EndNote format (Macintosh & Windows), MLA, ProCite - RIS format (Macintosh & Windows), RefWorks, Reference Manager - RIS format (Windows only), Turabian

Issue

Vol 1 No 1 (2017): JHSM (Febuary 2017)

Section

Articles

Creative Commons License This work is licensed under a Creative Commons Attribution 4.0 International License